Modern aspects of diagnosis and treatment of chi heart failure: what’s new?


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This review article is devoted to new trends in the diagnosis and treatment of chronic heart failure (CHF). In contrast to previous years, arterial hypertension predominates in the etiological structure of CHF. Among methods of diagnosis of CHF, determination of natriuretic peptide levels and ultrasound examination of the heart play leading role. The revised criteria for diagnosis of systolic and diastolic myocardial dysfunction using echography and Doppler sonography are presented. Background therapy of CHF therapy is based on the use of three groups of drugs: angiotensin converting enzyme inhibitors, ß-blockers and mineralocorticoid receptor antagonists. The new perspectives in the treatment of CHF related to the use of ivabradine and neprilysin inhibitor in combination with sartans are discussed.

Full Text

Restricted Access

About the authors

Igor I. Shaposhnik

South Ural State medical university

Email: shaposhnik@yandex.ru
MD, professor, Head of the Department of propaedeutics of internal diseases

References

  1. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (4-й пересмотр). Сердечная недостаточность. 2013;7:379-472. [National guidelines for the diagnosis and treatment of CHF (4th revision). Heart failure. 2013;7:379-472 (in Russ.)]
  2. Фомин И.В. Эпидемиология хронической сердечной недостаточности в Российской Федерации. В кн.: Хроническая сердечная недостаточность. М.: ГЭОТАР-Медиа, 2010. С. 7-77. [Fomin I.V. Epidemiology of chronic heart failure in the Russian Federation. In the book: Chronic heart failure. M.: GEOTAR-Media, 2010. P. 7-77 (in Russ.])
  3. Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. Хроническая сердечная недостаточность. М.: ГЭОТАР-Медиа, 2006. 532 с. [Belenkov Yu.N., Mareev V.Yu., Ageev F.T. Chronic heart failure. M.: GEOTAR-Media, 2006. 532 p. (in Russ.])
  4. Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность артериальной гипертонии в обследованных выборках Российской Федерации. Кардиология. 2014;10:4-12. [Chazova I.Ye., Zhernakova Yu.V., Oshchepkova Ye.V. etc. The prevalence of arterial hypertension in the examined samples in the Russian Federation. Kardiologiia. 2014;10:4-12 (in Russ.)]
  5. Диагностика и лечение артериальной гипертонии (клинические рекомендации). Кардиологический вестник. 2015;1:5-30. [Diagnosis and treatment of hypertension (clinical practice guidelines). Kardiologicheskij vestnik. 2015; 1:5-30 (in Russ.)]
  6. Лукьянова M.M., Бойцов C.A., Марцевич С.Ю. и др. Диагностика, лечение и сопутствующие заболевания у больных с диагнозом «фибрилляция предсердий» в условиях реальной амбулаторно-поликлинической практики (РЕКВАЗА). Рациональная фармакотерапия в кардиологии. 2014;4:366-71. [Lukyanova М.М., Boytsov S.A., Martsevich S.Yu. and. Diagnosis, treatment and comorbidities in patients with a diagnosis of «atrial fibrillation» in real outpatient practice (RAQUAZA). Rational pharmacotherapy in cardiology. 2014;4:366-71 (in Russ.)]
  7. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. do і : 10.1093/ eurheartj/ehwl 28.
  8. Овчинников А.Г., Агеев Ф.Т. Ультразвуковые исследования в оценке диастолического давления в левом желудочке. Сердечная недостаточность. 2009;10:221-6. [Ovchinnikov A.G., Ageev F. Т.Ultrasound in the evaluation of diastolic pressure in the left ventricle. Heart failure. 2009;10:221-6 (in Russ.)]
  9. McMurray J., Packer M., Desai A. Gong J., Lefkowitz M.P., Rizkala A.R., Rouleau J.L., Shi V.C., Solomon S.D., Swedberg K., Zile M.R.; PARADIGM-HF Investigators and Committees. Angiotensin-neprylisin inhibition versus enalapril in heart failure. N. Engl. J. Med. 2014;371:993-1004.
  10. Шапошник И.И. Трудности применения ß-блокаторов при хронической сердечной недостаточности: пути преодоления. РМЖ. 2015;27:1617-21. [Shaposhnik I.I. Difficulties of application of β-blockers in chronic heart failure: ways to overcome. Russian medical journal. 2015;27:1617-21 (in Russ.)]
  11. Ford I. Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: The SHIFT Risk Model. Int. J. Cardiol. 2015;184:163-9.
  12. Tardif J.C. Effects of selective heart rate reduction with ivabradine on left ventricular remodeling and function. Eur. Heart J. 2011 ;32(20):2507-15.
  13. Fox K., Komajda M., Ford I., Robertson M., Böhm M., Borer J.S., Steg P.G., Tavazzi L., Tendera M., Ferrari R., Swedberg К. Effect of ivabradine in patients with left-ventricular systolic dysfunction. Eur. Heart J. 2013;34(29):2263-70.
  14. Лопатин Ю.М. Оценка антиангинальной эффективности ивабрадина у больных ишемической болезнью сердца, осложненной сердечной недостаточностью. Кардиология. 2015;5:5-11. [Lopatin Yu.М. Evaluation of the antianginal efficacy of ivabradine in patients with coronary heart disease complicated by heart failure. Kardiologiia. 2015;5:5-11 (in Russ.)]
  15. Volteranі M., Cice G., Gaminiti G., Vitale C., D'Isa S., Perrone Filardi P., Acguistapace F., Marazzi G., Fini M., Rosano G.M. Effect of carvedilol, ivabradine or their combination on exercise capacity in patients with heart failure. Int. J. Cardiol. 2011 ; 151 ( 2) : 218-24.
  16. Гиляревский С.P., Голшмид М.В., Кузьмина И.М. Роль антагонистов рецепторов альдостерона в профилактике и лечении сердечно-сосудистых и почечных заболеваний: реальность и перспективы. РМЖ. 2014;23:1689-98. [Gіlyarevsky S.R., Goldshmid M.V., Kuzmina I.M. The role of aldosterone receptor antagonists in the prevention and treatment of cardiovascular and renal diseases: reality and prospects. Russian medical journal. 2014;23:1689-98 (in Russ.)]
  17. Zannad F., Alla F., Dousset B., Perez A., Pitt B. Limitation of exces- sive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation. 2000;102:2700-6.
  18. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., Gatlin M.; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial dysfunction. N. Engl. J. Med. 2003;348:1309-21.
  19. Fonarow G., Yancy C., Hernandez A., Peterson E.D., Spertus J.A., Heidenreich P.A. Potential impact of optimal implementation of evidence- based heart failure therapies on mortality Am. Heart J. 2011 ; 161:1024-30.
  20. Mak G., Ledwidge M., Watson C., Phelan D.M., Dawkins I. R., Murphy N. F., Patle A. K., Baugh J.A., McDonald K.M. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J. Am. Coll. Cardiol. 2009;54:1674-82.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies